Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01217619 | Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.(ML25444) | completed | Phase 2 | 25 | Baohui HanOTHER | 1 | Sep 12, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01858389 | A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 41 | PfizerINDUSTRY | 2 | Jul 18, 2017 | clinicaltrials |
| NCT00655850 | Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 39 | University of Alabama at BirminghamOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT01733589 | Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC | completed | Phase 1 / Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT01909752 | Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 12 | UbiVacINDUSTRY | 1 | Jul 6, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01233687 | AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 49 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02064491 | Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC | completed | Phase 2 | 18 | Finnish Lung Cancer GroupOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT01685060 | LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib | completed | Phase 2 | 140 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 19, 2017 | clinicaltrials |
| NCT01948141 | Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | completed | Phase 2 | 6 | Roswell Park Cancer InstituteOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT00942825 | Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)(CBP08-02) | completed | Phase 2 | 195 | CanBas Co. Ltd.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT01438307 | Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01166204 | Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD) | completed | Phase 2 | 300 | Maastricht Radiation OncologyOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00480831 | A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) | completed | Phase 2 | 128 | Genentech, Inc.INDUSTRY | 0 | May 18, 2017 | clinicaltrials |
| NCT00076856 | Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247) | completed | Phase 2 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT00831545 | Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) | completed | Phase 2 | 162 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 9, 2017 | clinicaltrials |
| NCT01023347 | A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer | completed | Phase 2 | 276 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT00188214 | CT Perfusion Scans for Assessment of Lung Cancer Before and After Chemo +/- Radiotherapy | completed | Phase 2 | 38 | University Health Network, TorontoOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00372203 | Endobronchial Ultrasound vs Mediastinoscopy in NSCLC | completed | Phase 2 | 200 | University Health Network, TorontoOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00408460 | Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 34 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01493843 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | completed | Phase 2 | 501 | Genentech, Inc.INDUSTRY | 16 | Apr 25, 2017 | clinicaltrials |
| NCT01138163 | Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer | completed | Phase 2 | 121 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT01160601 | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | completed | Phase 2 | 86 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT00622193 | Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer | completed | Phase 2 | 228 | Helsinn Therapeutics (U.S.), IncINDUSTRY | 2 | Apr 14, 2017 | clinicaltrials |
| NCT01153984 | A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations(BIOTEC) | completed | Phase 2 | 23 | Hoffmann-La RocheINDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01951690 | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | completed | Phase 2 | 55 | Verastem, Inc.INDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00642759 | Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00453362 | A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib | completed | Phase 1 / Phase 2 | 88 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT00854308 | A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib) | completed | Phase 2 | 137 | Genentech, Inc.INDUSTRY | 0 | Mar 31, 2017 | clinicaltrials |
| NCT00499655 | Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 2 | 107 | City of Hope Medical CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00215930 | The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 53 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT00963807 | A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2017 | clinicaltrials |
| NCT00094861 | Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 100 | Swedish Orphan BiovitrumINDUSTRY | 0 | Mar 14, 2017 | clinicaltrials |
| NCT00227019 | Phase 2 Trial of Bevacizumab in Combination With Pemetrexed | completed | Phase 2 | 16 | Heather WakeleeOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00231465 | Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00775385 | TAilored Post-Surgical Therapy in Early Stage NSCLC(TASTE) | completed | Phase 2 / Phase 3 | 152 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00874107 | Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 90 | HiberCell, Inc.INDUSTRY | 2 | Mar 3, 2017 | clinicaltrials |
| NCT00906282 | Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT00564733 | FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer | completed | Phase 2 | 55 | University of WashingtonOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00492206 | Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC | completed | Phase 2 | 40 | University of PittsburghOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT00842712 | Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)(CERTO) | completed | Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 8 | Jan 13, 2017 | clinicaltrials |
| NCT00098540 | Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Dec 29, 2016 | clinicaltrials |
| NCT00073723 | Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 75 | Celgene CorporationINDUSTRY | 1 | Dec 15, 2016 | clinicaltrials |
| NCT00874848 | Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | HiberCell, Inc.INDUSTRY | 2 | Nov 29, 2016 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT00124280 | Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 85 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01070927 | An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Sep 12, 2017source: clinicaltrials